Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a ...
Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...
Please provide your email address to receive an email when new articles are posted on . In 2026, Stelara will be discounted 66% from its list price for Medicare users, while Enbrel will be discounted ...
A drugmaker whose product could be the first subjected to a price cap in Colorado is suing to throw out the state board that deemed its medication unaffordable. In February, the Colorado Prescription ...
Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...
An advisory panel for the Food and Drug Administration concluded Wednesday that Switzerland.-based Novartis AG’s version of Amgen’s arthritis drug Enbrel should be approved, according to Reuters. The ...
A Colorado board voted unanimously Friday to consider setting a maximum price for a drug to treat autoimmune diseases, launching the state into uncharted territory and setting up a possible showdown ...
Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts’ expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel. The ...
Colorado could soon cap how much the state will pay for Amgen’s autoimmune drug Enbrel — in what would be the first such move from a state prescription drug affordability board. Affordability boards ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results